Lower levels of these inhibitors might, therefore, imply a TME that is less adept at evading immune surveillance, thereby facilitating a more robust immune-mediated tumor rejection despite the numerically lower presence of CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.